Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYBB | P04839 | 1/20 | 0.49 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.49 |
| ▸ | NOX3 | Q9HBY0 | 1/20 | 0.49 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.49 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 6/20 | 0.48 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6789794 | 0.88 | SCN9A (0.44) | CYBBNOX5NOX3NOX4NOX1 | |
| SCHEMBL3236690 | 0.85 | ROCK2 (0.53) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6788466 | 0.84 | HRH4 (0.44) | CYBBNOX5NOX3NOX4NOX1 | |
| SCHEMBL6788753 | 0.82 | KMT2A (0.50) | LMNAMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL6789948 | 0.81 | KDM4E (0.47) | CYBBNOX5NOX3NOX4NOX1 | |
| SCHEMBL6785059 | 0.79 | HRH4 (0.43) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6791293 | 0.79 | MAPT (0.53) | LMNACYP2C9HTR2CHTR2AMAPT | |
| SCHEMBL6791292 | 0.78 | DRD4 (0.44) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6784619 | 0.78 | LMNA (0.43) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6353199 | 0.77 | TRPV1 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127502-A1 | Use of GAL3 antagonist for treatment of depression | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127502-A1 | Use of GAL3 antagonist for treatment of depression | GALR3, GALR2, GALR1 | CYBB 3414/4885NOX5 2045/4885NOX3 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.